Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases
Related Posts
Thorp M, Balakasi K, van Oosterhout JJ, Ramesh M, Robson I, Choko A, Shoptaw S, Hoffman R, Cornell M, Dovel K. High-Risk Mobility and Interruption[...]
Heerspink HJL, Neuen BL, Agarwal R, Cherney DZI, Lam CSP, Tuttle KR, Wanner C, Sarafidis P, Chertow GM, Friede T, Barratt J, Floege J, Chew-Wong[...]
Song J, Daniel M, Ardehali A. Not Yet a Nail in the Coffin for Ex Vivo Heart Perfusion. Ann Thorac Surg. 2026 Nov 15:S0003-4975(26)01175-6. doi:[...]